Roche buys precision medicine firm Ignyta for $1.7B

(By Anuja Vaidya for Becker’s Hospital Review)

Roche, a global pharmaceuticals and diagnostics company, is acquiring Ignyta for $27 per share in an all-cash transaction. This corresponds to a total transaction value of $1.7 billion on a fully diluted basis. Continue reading article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.